OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
Protein OTUD7B plays complex roles in cancer and heart health
This systematic review examines the molecular roles of OTUD7B across multiple malignancies and inflammatory models. The findings indicate th…
A protein called OTUD7B acts as a double-edged sword, helping some conditions while fueling the growth of others.
Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
Attenuated R-THP-COP regimen shows promise for elderly diffuse large B-cell lymphoma
This case report describes an 85-year-old female patient with diffuse large B-cell lymphoma treated with an attenuated R-THP-COP regimen. Th…
An 85-year-old woman achieved complete radiological response and remained symptom-free for three years on an attenuated chemotherapy regimen…
Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
Zanubrutinib shows high response rates in diffuse large B-cell lymphoma patients
A meta-analysis of 1,346 patients with diffuse large B-cell lymphoma shows zanubrutinib achieves high response rates and prolonged survival.…
Zanubrutinib helped 95 out of 100 previously untreated patients with diffuse large B-cell lymphoma respond to treatment in this analysis.
Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
New immunotherapy options offer high response rates for Diffuse Large B-Cell Lymphoma patients
This narrative review surveys immunotherapy options for diffuse large B-cell lymphoma beyond rituximab, including bispecific antibodies, CAR…
New immunotherapy treatments show high response rates for Diffuse Large B-Cell Lymphoma, offering hope beyond the standard 60% success rate …
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
CAR-T Trials Show Promise But Face Big Hurdles For Lymphoma Patients
This systematic landscape review of 360 CAR-T cell therapy trials for non-Hodgkin lymphoma found rapid expansion with a predominant focus on…
New research shows that CAR-T cell trials are expanding quickly but scientists must solve big problems like drug resistance before patients …
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
New cancer therapies double response rates for tough lymphoma
This systematic review and meta-analysis of phase 1-2 trials evaluated experimental agents alone or combined with CD20-antibodies in adults …
Patients with aggressive lymphoma once had few options after standard treatments failed, but new therapies are changing that outlook in ways…
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
Mecapegfilgrastim reduces grade 3+ neutropenia in treatment-naive diffuse large B-cell lymphoma patients versus no prophylaxis
New Drug Cuts Severe Infection Risk In Lymphoma Care
This randomized controlled trial evaluated mecapegfilgrastim in 42 treatment-naive patients with diffuse large B-cell lymphoma.
A new long-acting injection lowers the risk of dangerous low white blood cell counts in lymphoma patients starting their first round of chem…
Research across Lymphoma
Related studies from across the Lymphoma family.
EBUS-TBNB yields higher diagnostic rates for lymphoma and sarcoidosis compared to EBUS-TBNA
Core Biopsy Shows Higher Yield for Lymphoma and Sarcoidosis
This meta-analysis of 1434 patients with mediastinal disorders found that EBUS-TBNB provides a significantly higher diagnostic yield for lym…
A core biopsy technique may provide more accurate results than standard needle aspiration for certain conditions like lymphoma and sarcoidos…
Hodgkin lymphoma survival exceeds 90% in early-stage patients with modern therapy
New treatments push Hodgkin lymphoma survival above 90%
This systematic review synthesizes outcomes in Hodgkin lymphoma, reporting 5-year survival exceeding 90% in early-stage patients and long-te…
For early-stage Hodgkin lymphoma, 5-year survival now exceeds 90%. Advanced disease remission tops 75%. But long-term toxicities remain a co…
Systematic review of preclinical CBD effects in canine cancers
Lab tests suggest CBD may help treat cancer in dogs
This is a systematic review of preclinical studies on cannabidiol for canine cancers. It synthesizes evidence of antiproliferative and proap…
Lab tests suggest CBD may help treat cancer in dogs by slowing growth and triggering cell death, though human use remains unproven.
Systematic review and meta-analysis links benzene exposure to increased lymphoid neoplasm risk
Benzene exposure linked to higher lymphoid neoplasm risk in large review
This systematic review and meta-analysis evaluated 95 human studies on benzene exposure across occupational and environmental settings. The …
A review of 95 studies shows benzene exposure is associated with a significantly higher risk of lymphoid neoplasms, including Hodgkin lympho…
Network meta-analysis compares EBUS techniques for mediastinal lymphadenopathy diagnostic yield
Doctors find a better way to sample swollen lymph nodes safely
This systematic review and network meta-analysis evaluated diagnostic yield across EBUS techniques in 2357 patients with mediastinal and/or …
A new freezing biopsy technique finds the cause of swollen chest nodes more often than standard needles while staying safe for patients.
Narrative review on gamma delta T cell therapies for hematologic malignancies and immune cytopenias
New T-Cells Fight Blood Cancer Without Matching Your DNA
This narrative review synthesizes evidence on gamma delta T cell therapies for acute leukemias, lymphomas, multiple myeloma, and immune cyto…
A new type of immune cell could finally treat blood cancers that other therapies cannot touch.
Narrative Review Discusses Combined BTK and Bcl-2 Inhibitors With CAR-T Cell Therapy for Lymphoma
Can combining targeted drugs with CAR-T therapy help lymphoma patients who have run out of options?
This narrative review evaluates the potential of combining small molecule targeted drugs, specifically BTK and Bcl-2 inhibitors, with CAR-T …
Combining targeted drugs with CAR-T therapy may help lymphoma patients who have run out of options by improving treatment effectiveness and …
Circulating protein signature predicts severe immune-related adverse events in relapsed/refractory lymphoma
Blood protein test may help predict severe side effects in lymphoma patients
A cohort study of 98 relapsed/refractory lymphoma patients at MD Anderson and Moffitt Cancer Centers found that a circulating protein signat…
A new blood test can spot lymphoma patients at high risk for severe immune reactions before dangerous side effects start.
All Non-Hodgkin's Lymphoma Articles
- OTUD7B acts as a context-dependent regulator in various cancers and inflammatory conditions
- Attenuated R-THP-COP regimen achieved complete response in an 85-year-old with diffuse large B-cell lymphoma
- Zanubrutinib Delivers High Response Rates And Survival Benefits Across Diffuse Large B-Cell Lymphoma Patient Groups In This Meta-Analysis
- Immunotherapies beyond rituximab show high response rates in diffuse large B-cell lymphoma
- Meta-analysis of double-expressor lymphoma prognoses and novel therapies
- Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
- Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
- Systematic landscape analysis of CAR-T trials for non-Hodgkin lymphoma finds early-phase focus
- FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
- Experimental agents show response rates up to 70% in relapsed or refractory diffuse large B-cell lymphoma
- FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
- Mecapegfilgrastim reduces grade 3+ neutropenia in treatment-naive diffuse large B-cell lymphoma patients versus no prophylaxis
- Fixed-duration subcutaneous mosunetuzumab shows favorable efficacy and safety versus IV in relapsed follicular lymphoma
- Case report documents HIV-associated diffuse large B-cell lymphoma regression with cART
- Eight-gene signature associated with survival in patients with Diffuse Large B-cell lymphoma
- Abexinostat showed a 69.5% objective response rate in relapsed follicular lymphoma patients
- Tisagenlecleucel in Korean patients with relapsed or refractory diffuse large B-cell lymphoma
- Review of case report discusses anti-PL-12 antisynthetase syndrome and NK/T-cell non-Hodgkin lymphoma
- Narrative review explores strategies to prevent CAR-T cell exhaustion in treatment-resistant non-Hodgkin lymphoma
- High FGR protein expression associated with worse relapse-free survival in de novo DLBCL patients treated with R-CHOP
- Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
- High-dose pegylated liposomal doxorubicin shows comparable survival to conventional doxorubicin in DLBCL with reduced toxicity
- CXCL13 quantification in PBMCs and plasma distinguishes Sézary syndrome from other cutaneous T-cell lymphomas and dermatoses
- Mitoxantrone liposome plus CMOP shows high response rates in untreated peripheral T-cell lymphoma patients
- CD5-positive DLBCL diagnosed in a 74-year-old woman via uterine drainage fluid analysis
- Phase 2 trial compares Inotuzumab Ozogamicin plus R-CVP for DLBCL patients unfit for anthracycline
- Systematic review finds highest glyphosate exposure associated with increased NHL risk
- Case report describes treatment response in rare dual-lesion DLBCL with heterogeneous subtypes
- R-CVP after radiotherapy improves progression-free survival in early-stage follicular lymphoma
- Case report describes management of Burkitt's lymphoma with concurrent HIV, CMV encephalitis, and salmonella bacteremia